In alternative embodiments, provided are chimeric immunogens or antigens, and methods for making and using them, including methods for making and obtaining polyclonal antibodies specific for selected epitopes. In alternative embodiments, provided are methods for generating an epitope-specific antibody response in a rabbit, wherein the immune response comprises generation of rabbit antibodies specifically against (or that specifically bind to) at least one human epitope, and the method comprises administering to a rabbit a sufficient amount of a chimeric or recombinant polypeptide to generate the epitope-specific antibody response. In alternative embodiments, provided are chimeric or recombinant polypeptides comprising: a ferritin polypeptide having conjugated or attached thereto by or via a substantially non-immunogenic linker an immunogenic peptide or polypeptide.

CAR-T cells for cancer therapy are provided with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes the VH amino acid sequence of SEQ ID NO: 36 and the VL amino acid sequence of SEQ ID NO: 38. The antibody preferably is provided with the amino acid sequence of SEQ ID NO: 32. Such CAR-T cells can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used.

This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.

The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.

The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-Tissue Factor Pathway Inhibitor (TFPI) antibody.

This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

Rabbit antigen binding protein nucleic acid libraries are provided (e.g., nucleic acid libraries encoding antigen binding proteins that specifically recognize a target peptide-MHC (pMHC)). Methods of producing the rabbit antigen binding protein nucleic acid libraries are also provided.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.